Summary
We report the first placebo controlled parallel group study of once daily endralazine (5–20 mg) in hypertension uncontrolled by a beta-blocker plus a diuretic.
Following a 4-week run-in period 22 patients with a sitting mean arterial pressure (MAP) greater than 110 mm Hg were entered into the study and received either endralazine 5 mg or placebo. Blood pressure was measured 2 h and 24 h after dosing and the drug dose doubled at 2 and 4 weeks if the 24-h MAP remained >110 mg Hg. The final blood pressure assessment was made after 6 weeks treatment in the 19 patients who completed the study. Three patients withdrew from the study because of side effects. The hypotensive effect (sitting) was in excess of placebo at 2 h by 15.8 mm Hg systolic (NS), 15.4 mm Hg diastolic (p<0.01), 15.5 mm Hg MAP (p<0.02) and at 24 hours by 7.7 mm Hg systolic (NS), 8.9 mm Hg diastolic (p<0.02) and 11.1 mm Hg MAP (p<0.02). This study suggests that endralazine should be prescribed twice daily.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McAreavey D, Ramsay LE, Latham L et al. (1984) “Third drug” trial comparative study of antihypertensive agents added to treatment when blood pressure uncontrolled by a beta-blocker plus thiazide diuretic. Br Med J 288: 106–111
Jounela AJ, Pasanen M, Mattila MJ (1975) Acetylator phenotype and the antihypertensive response to hydralazine. Acta Med Scand 197: 303–306
Ramsay LE, Silas JH, Ollerenshaw JD, Tucker GT, Phillips FC, Freestone S (1984) Should the acetylator phenotype be determined when prescribing hydralazine for hypertension? Eur J Clin Pharmacol 26: 39–42
Cameron HA, Ramsay LE (1984) The lupus syndrome induced by hydralazine: A common complication with low dose treatment. Br Med J 289: 410–412
Reece PA, Cozamanis I, Zacest R (1982) Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator, antihypertensive endralazine. Eur J Clin Pharmacol 23: 523–527
Holmes DG, Bogers WA, Wideroe TE, Huunan-Seppala A, Wideroe B (1983) Endralazine, a new peripheral vasodilator: Absence of effect of acetylator status on antihypertensive effect. Lancet 1: 670–671
Bogers WA, Meems L (1983) Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period. Eur J Clin Pharmacol 24: 301–305
Kirch W, Axthelm T (1982) Endralazine, a new peripheral vasodiator — a randomised cross-over against dihydralazine. J Cardiovasc Pharmacol 4: 562–566
Elliot HL, McLean K, Sumner DJ, Donnelly RJ, Reid JL (1982) Clinical evaluation of endralazine (BQ 22708), a new vasodilator in essential hypertension. Clin Exp Hyperten 4 [8]: 1409–1418
Hoffman JJ, Thien TH, Van't Laar A (1983) Effects of intravenous endraliazine in essential hypertension. Br J Clin Pharmacol 16: 39–44
Kingswood JC, Banks RA, Harrison PR, Higgs E, Mackenzie JC (1983) Long-term effects of endralazine (BQ 22708) in patients with renal impairment and hypertension. Postgrad. Med J 59 [Suppl 3]: 173–176
Evans DAP (1969) An improved and simplified method of detecting the acetylation phenotype. J Med Genet 6: 405–407
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McGourty, J.C., Silas, J.H. & Pidgeon, J. Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diuretic. Eur J Clin Pharmacol 29, 401–403 (1985). https://doi.org/10.1007/BF00613452
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613452